Literature DB >> 8536056

Regulation of growth hormone (GH), insulin-like growth factor (IGF)I, IGF binding proteins -1, -2, -3 and GH binding protein during progression of liver cirrhosis.

J Kratzsch1, W F Blum, E Schenker, E Keller.   

Abstract

The aim of this study was to investigate the regulation of various proteins of the GHIGF axis during progression of liver failure and to search for potential prognostic markers of functional hepatic reserve. Serum levels of growth hormone (GH) and high affinity growth hormone binding protein (GHBP), insulin-like growth factor I (IGF-I) and IGF binding proteins (IGFBP) -1, -2 and -3 were determined in patients with liver cirrhosis. A continuous decline in the concentrations of IGF-I, IGFBP-3 and serum GH-binding activity (GHBP) was observed during progression of cirrhosis and the data correlated significantly with choline esterase, total serum protein and the Child score. In addition, GHBP showed a significant correlation with the enzymatic activity of glutamate dehydrogenase or transaminases and seems so to be influenced by the degree of liver cell damage. In contrast, IGFBP-1 and IGFBP-2 levels were significantly elevated in preterminal disease suggesting an upregulatory mechanism is still effective in this situation. Only when liver function had markedly deteriorated, the serum levels of these two parameters decreased again, possibly due to an impaired synthesis. The excellent correlation between the serum levels of IGF-I (r = -0.64, p < 0.001) or IGFBP-3 (r = -0.67, p < 0.001) and the Child score index suggests that they reflect the hepatic functions just as conventional indicators. For an appropriate interpretation of the liver function the measurement of the growth related peptides can be a valuable tool to estimate pathological alteration in the functional hepatic reserve or in the glucose homeostasis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8536056     DOI: 10.1055/s-0029-1211366

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  7 in total

1.  Clinical examples of disturbed IGF signaling: intrauterine and postnatal growth retardation due to mutations of the insulin-like growth factor I receptor (IGF-IR) gene.

Authors:  W Kiess; J Kratzsch; E Keller; A Schneider; K Raile; J Klammt; B Seidel; A Garten; H Schmidt; R Pfäffle
Journal:  Rev Endocr Metab Disord       Date:  2005-08       Impact factor: 6.514

2.  Regenerative potential of platelets in patients with chronic kidney disease.

Authors:  Elżbieta Cecerska-Heryć; Rafał Heryć; Magda Wiśniewska; Anna Michalczyk; Barbara Dołęgowska
Journal:  Int Urol Nephrol       Date:  2019-06-13       Impact factor: 2.370

3.  Serum prolidase and IGF-1 as non-invasive markers of hepatic fibrosis during four different periods after bile-duct ligation in rats.

Authors:  Orhan Tarçin; Nursal Gedik; Berna Karakoyun; Veysel Tahan; Gagan Sood; Ciğdem Celikel; Nurdan Tözün
Journal:  Dig Dis Sci       Date:  2007-11-13       Impact factor: 3.199

4.  Expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor and its intervention by interleukin-10 in experimental hepatic fibrosis.

Authors:  Xiao-Zhong Wang; Zhi-Xin Chen; Li-Juan Zhang; Yun-Xin Chen; Dan Li; Feng-Lin Chen; Yue-Hong Huang
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

5.  Insulin-like growth factors in patients with liver cysts.

Authors:  Olgica Nedić; J Anna Nikolić; Ivona Baricević; Biljana Jovanović; Natasa Ilić
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

6.  Low Growth Hormone Levels Predict Poor Outcome of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.

Authors:  Daxian Wu; Lingjian Zhang; Shanshan Ma; Yalei Zhao; Ronggao Chen; Fen Zhang; Qiuhong Liu; Xiaowei Xu; Zhongyang Xie
Journal:  Front Med (Lausanne)       Date:  2021-07-06

Review 7.  IGF-I measurements in the diagnosis of adult growth hormone deficiency.

Authors:  Anita Y M Kwan; Mark L Hartman
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.